Eyecelerator@AAO 2021

Thursday, November 11, 2021

Ernest N. Morial Convention Center
New Orleans

Bring the future of ophthalmology into focus. 

Breakfast + Registration

7:00 – 8:00 a.m.

8:00 – 8:05 a.m.

Welcome and Overview of Eyecelerator @ AAO 2021

David W. Parke II, MD; Steve Speares; Gil Kliman, MD, Program Director



2021 Advances in Ophthalmic Innovation: Clinical, Commercial, and Capital Markets

8:05 – 8:30 a.m.

2021 Advances in Ophthalmic Innovation: Clinical, Commercial, and Capital Markets

Moderators: Jim Mazzo and Tom Mitro


  • Kristen Harmon Ingenito, MBA, Vice President, Director of Ophthalmics, Market Scope 

  • Michael Giaquinto, Senior Managing Director, Medical Supplies & Devices, SVB Leerink 

The Magic of Unicorns:  How Digital Giants Can Enlighten Ophthalmology 

8:30 – 9:15 a.m.

Join moderators Ranya G. Habash, MD and Gil Kliman, MD, when they engage a cohort of leading experts to probe how the digital ophthalmology market is evolving right now. The panel will also forecast the impact of new technology on patient care, clinical data and innovation.​ 

Overview of Digital Health Marketplace 

Reed Welch, Managing Director, Raymond James
The session kicks off with an informed overview of the digital health marketplace and a valuable, clear-eyed assessment of what innovators and investors have learned from the recent success of digital “unicorns.”


Moderators: Ranya G. Habash, MD and Gil Kliman, MD


  • Hylton Kalvaria, Chief Business Officer, Verana Health

  • Paul McRae, Global Healthcare and Digital Transformation Strategist, Amazon

  • Pam Nesbitt, Global Healthcare Lead, CSE, Microsoft

  • Euan S. Thomson, PhD, President Ophthalmic Devices, Head of Digital Business Unit, Zeiss Medical Technology

  • Reed Welch, Managing Director, Raymond James

Cornea Spotlight
Will Cornea Transplantation Become Obsolete?

9:15 – 10:00 a.m.

Will Cornea Transplantation Become Obsolete?


Moderators: Zaina Al-Mohtaseb, MD and Deepinder K. Dhaliwal, MD, L.Ac.


  • Bala Ambati, MD, PhD, MBA, Co-Founder & President, iVeena

  • Nazneen Aziz, PhD, Chief Scientific Officer, Avellino Labs

  • Chuck Hess, Vice President and General Manager, US Surgical, Bausch + Lomb

  • Elizabeth Yeu, MD, Assistant Vice President/Medical Director, Virginia Eye Consultants/Virginia Surgery Center


Treating Keratoconus in 2021 
Zaina Al-Mohtaseb, MD

Panel Discussion – What’s New? 


Treating Endothelial Dystrophy in 2021

Deepinder K. Dhaliwal, MD, L.Ac.


What will replace Endothelial Keratoplasty? 

  • Brian Levy OD, MSc, CMO, EyeYon Medical

  • Greg Kunst, Chief Executive Officer, Aurion Biotech

Panel Discussion  

Networking Break

10:00 – 10:30 a.m.

The Intersection of Reimbursement and Innovation

10:30 – 11:15 a.m.

Proposed reimbursement cuts and the evaluation of physician services will have a ripple effect with aftershocks throughout our industry. This session will forecast the impact on investment, innovation, patient care, and physician practice patterns from the perspective of practicing surgeons, industry leaders, and reimbursement experts.

Moderators: Leon W. Herndon, MD and Thomas W. Samuelson, MD


  • Jeannette Bankes, Alcon, President and GM Surgical

  • Frank R. Burns, MD, Government Relations Committee Member, ASCRS

  • Erin Powers, MBA, Vice President, Global Marketing & Product Strategy, BVI Medical 

  • Nathan M. Radcliffe, MD, Associate Clinical Professor of Ophthalmology, Mount Sinai School of Medicine

  • George A. Williams, MD, Senior Secretary for Advocacy, American Academy of Ophthalmology

Retina Spotlight
Meet the Game-Changing Innovators With the Most Promising Strategies For Impacting Retina 

11:15 a.m. – 12:00 p.m.

 Moderators Robert L. Avery, MD and Allen C. Ho, MD, will get five innovative companies to open their playbooks and reveal the newest treatments and technologies for retina, while panel experts add insight and analyze the market opportunities.

Moderators: Robert L. Avery, MD and Allen C. Ho, MD


  • Wiley Chambers, MD, Supervisory Medical Officer, Ophthalmology, FDA 

  • Kevin Clark, Vice President, Ophthalmology Commercial Business Unit, Regeneron

  • Ram Palanki, Senior Vice President of Commercial Strategy & Operations, REGENXBIO, Inc.

  • Reginald J. Sanders, MD, Retina Group of Washington

  • Namrata Saroj, OD, Principal, All Eyes Consulting 

Presenting Companies:

  1. Annexon Biosciences
    Michael Overdorf, MBA, Executive Vice President & Chief Business Officer


  2. Apellis Pharmaceuticals
    Cedric Francois, MD, PhD, CEO


  3. GenSight Biologics
    Magali Taiel, MD, Chief Medical Officer


  4. Nanoscope Therapeutics 
    Samarendra Mohanty, PhD, Co-Founder and President


  5. Opus Genetics 
    Benjamin Yerxa, PhD, Acting CEO 

Lunch and Networking

12:00 – 1:00 p.m.

Company Showcase Breakout Rooms

1:00 – 2:30 p.m.

A diverse line up of more than 30 companies, from startups to public, will present innovations at all stages in a unique, interactive format. Showcases will include five-minute company presentations followed by a moderated Q+A with panels of seasoned strategics, investors, and KOLs. Audience members will also be invited to ask questions. 


Separate breakout rooms will operate simultaneously for each subspecialty. Follow links for company showcase schedules:








Networking Break

2:30 – 3:00 p.m.

New Category Spotlight
Myopia Control: Corrective Lenses, Drugs and Diagnostics

3:00 – 3:45 p.m.

Co-moderators Michael X. Repka, MD and Gil Kliman, MD, engage a panel of new category product innovators striving to mitigate the rapid global rise of myopia through early interventions. Join us for a wide-ranging discussion including a market overview and insights from large and small companies pioneering this new space.

Co-Moderators: Michael X. Repka, MD and Gil Kliman, MD

Overview of Myopia Pandemic
Michael X. Repka, MD, Vice Chair for Clinical Practice, Wilmer Eye Institute

Overview of Companies and Products in the Myopia Control Marketplace

Michael Lachman, President, EyeQ Research



  • Thomas W. Chalberg, PhD, MBA, Founder, Exhaura, Ltd.

  • Paul Chamberlain, Director, Research Programs, CooperVision 

  • Wiley Chambers, MD, Supervisory Medical Officer, Ophthalmology, FDA

  • Sean Ianchulev, MD, MPH, Founder and CEO, Eyenovia

  • Rajesh K. Rajpal, MD, Chief Medical Officer and Global Head of Clinical and Medical Affairs, Johnson & Johnson Vision

What's Keeping Industry Leaders Up at Night? 

3:45 – 4:30 p.m.

This can’t-miss session promises a rare insider's look at the global business of ophthalmology from some of the most forward-thinking executive leaders.


Industry veteran Jim Mazzo will dig deep for insights about each company’s business strategy, examine how the industry is positioned to address key market needs, and even uncover which business challenges remain unsolved for global strategics. 


Moderator: Jim Mazzo, Executive Chair, Neurotech Pharmaceuticals 


  • Ian Bell, President, Global Business and Innovation, Alcon

  • Chris M. Calcaterra, MBA, Chief Operating Officer, Glaukos

  • Jag Dosanjh, SVP, Medical Therapeutics, Allergan, an AbbVie company

  • Warren Foust, Worldwide President, Surgical, Johnson & Johnson

  • Shervin Korangy, President and CEO, BVI Medical 

  • Tom Mitro, President and COO, Aerie Pharmaceuticals

  • Anthony J. Wallace, MBA, VP & Franchise Head, U.S. Ophthalmics, Novartis Pharmaceutical Corp.

Closing Bell

4:30 – 5:00 p.m.

Moderator: Gil Kliman, MD 

Review of Top Three Companies

Deepinder Dhaliwal MD, L.Ac.

Allen C. Ho MD 

Thomas W. Samuelson, MD 

Eyes on the Future: What's Coming in 2022  

Moderator: Gil Kliman, MD 


  • Deepinder K. Dhaliwal, MD, L.Ac.

  • Allen C. Ho, MD

  • Thomas W. Samuelson, MD

  • Jim Mazzo  

  • Tom Mitro 

Closing Remarks - Gil Kliman, MD 

Networking Reception

5:00 – 5:45 p.m.